Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Long-term effect of epalrestat on cardiac autonomic neuropathy in subjectswith non-insulin dependent diabetes mellitus
Autore:
Ikeda, T; Iwata, K; Tanaka, Y;
Indirizzi:
Tottori826,v, Coll Med Care Technol, Dept Med Technol, Yonago, Tottori 6830 Tottori Univ Yonago Tottori Japan 6830826 d Technol, Yonago, Tottori 6830 Tottori Univ, Fac Med, Dept Internal Med 1, Yonago, Tottori 683, Japan Tottori Univ Yonago Tottori Japan 683 l Med 1, Yonago, Tottori 683, Japan
Titolo Testata:
DIABETES RESEARCH AND CLINICAL PRACTICE
fascicolo: 3, volume: 43, anno: 1999,
pagine: 193 - 198
SICI:
0168-8227(199903)43:3<193:LEOEOC>2.0.ZU;2-F
Fonte:
ISI
Lingua:
ENG
Soggetto:
ALDOSE REDUCTASE INHIBITOR; QT INTERVAL PROLONGATION; TESTS; AGE;
Keywords:
aldose reductase inhibitor; cardiovascular autonomic neuropathy; CVR (R); epalrestat;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
15
Recensione:
Indirizzi per estratti:
Indirizzo: Ikeda, T Tottorionago, Coll Med Care Technol, Dept Med Technol, Nishi Machi 133-2, Y Tottori Univ Nishi Machi 133-2 Yonago Tottori Japan 6830826 -2, Y
Citazione:
T. Ikeda et al., "Long-term effect of epalrestat on cardiac autonomic neuropathy in subjectswith non-insulin dependent diabetes mellitus", DIABET RE C, 43(3), 1999, pp. 193-198

Abstract

To evaluate the effect of long-term administration of an aldose reductase inhibitor on diabetic cardiovascular autonomic neuropathy, 22 subjects withnon-insulin dependent diabetes mellitus (NIDDM, 11 men and 11 women, mean age; 64.8 +/- 7.8 years, duration of diabetes; 18.3 +/- 5.6 years) were administered epalrestat, one type of aldose reductase inhibitor, for 36 months. The changes in the coefficient of variation of the R-R interval (CVR R) during rest and the QTc interval were compared with 43 age-matched NIDDM (controls). During the study, the CVR R value gradually decreased in the controls, while it slightly increased in subjects treated with epalrestat. After36 months, the CVR R. value (2.31+/-1.09%) in subjects treated with epalrestat was significantly (P<0.05) higher than that (1.84 +/- 0.75%) in the controls. There were no significant differences in QTc intervals in both groups. These results suggest that long-term administration of an aldose reductase inhibitor may be available for cardiac autonomic neuropathy in even relatively older diabetic subjects with long duration. (C) 1999 Elsevier Science Ireland Ltd. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/11/20 alle ore 06:52:38